Shareholders Foundation, Inc.

Agile Therapeutics Inc (NASDAQ:AGRX) Shareholder Notice: Deadline in Lawsuit on March 7, 2017

A Deadline is coming up on March 7, 2017 in the lawsuit for investors in Agile Therapeutics Inc (NASDAQ:AGRX) and NASDAQ:AGRX stockholders should contact the Shareholders Foundation.

 

San Diego, CA -- (SBWIRE) -- 02/28/2017 -- The Shareholders Foundation announces that a deadline is coming up on March 7, 2017 in the lawsuit filed for investors of Agile Therapeutics Inc (NASDAQ:AGRX) over alleged securities laws violations by Agile Therapeutics Inc

Investors who purchased shares of Agile Therapeutics Inc (NASDAQ:AGRX) have certain options and there are strict and short deadlines running. Deadline: March 7, 2017. NASDAQ:AGRX stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call 858-779-1554.

According to the complaint filed in the U.S. District Court for the District of New Jersey the plaintiff alleges on behalf of certain purchasers of Agile Therapeutics Inc (NASDAQ:AGRX) common shares that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that between March 9, 2016 and January 3, 2017 the Defendants allegedly failed to disclose that the Twirla contraceptive patch had an efficacy rating that fell below peer group standards, that over half of patients in its "Secure" Phase 3 Study discontinued the study early, that the Twirla patch therefore allegedly had a slight chance of FDA approval, and that, as a result of the foregoing, Defendants' statements about Agile Therapeutics' business, operations, and prospects, were false and misleading and/or lacked a reasonable basis.

On January 3, 2017, Agile Therapeutics Inc (NASDAQ:AGRX) announced top-line results from its Phase 3 SECURE clinical trial of Twirla®, its investigational low-dose combined hormonal contraceptive patch. The study, which was initiated at the request of the FDA, comes after the FDA rejected Agile's initial marketing application back in 2013. The Company cited "positive top-line results" in the study, yet reported that almost 2% of subjects experienced "serious adverse events" including "deep vein thrombosis, pulmonary embolism, gallbladder disease, ectopic pregnancy and depression." Shares of Agile Therapeutics Inc (NASDAQ:AGRX) declined to as low as $1.82 per share on January 4, 2017.

On February 27, 2017, NASDAQ:AGRX shares closed at $2.29 per share.

Those who purchased shares of Agile Therapeutics Inc have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com